Sign In
XRAY.US
id: 1528

Dentsply Sirona (XRAY) $84M Investor Settlement

Eligible claimants can submit their claims for compensation.
$84,000,000
Cash Settlement
E.D. New York
Court
1:18-cv-07253
Case number
12/08/2015
Class period Start
08/06/2018
Class period End
10/07/2025
Claim deadline
Dentsply Sirona ($XRAY) has agreed to an $84 million settlement with investors over claims that it misled them about financial reporting and anti-competitive practices.

Outline


Between 2014 and 2018, Dentsply Sirona allegedly inflated sales by forcing distributors like Patterson Companies to purchase excess inventory and overstated goodwill tied to those deals. The company was also accused of coordinating with major dental distributors to limit competition and maintain inflated pricing. As these issues came to light, $XRAY dropped over 45%, and Dentsply faced a lawsuit from investors.

Timeline

  • September 30, 2017 – Patterson Companies declined to renew its exclusive distribution agreement, exposing Dentsply Sirona’s reliance on inflated sales metrics.
  • August 7, 2018 – The company disclosed a $1.2 billion goodwill impairment, causing $XRAY to fall 19%.
  • December 19, 2018 – Investors filed a lawsuit, alleging fraudulent financial reporting and anti-competitive conduct.
  • December 16, 2020 – The SEC issued a cease-and-desist order, confirming Dentsply Sirona failed to disclose inventory risks and violated financial reporting rules.
  • March 14, 2025 – Dentsply Sirona agreed to pay a $84 million settlement.

Background


Dentsply Sirona positioned itself as the world’s largest manufacturer of professional dental products, reporting strong sales growth based on exclusive distribution agreements with Patterson Companies.
These agreements required Patterson to purchase large volumes of inventory, even when demand was lower, inflating Dentsply Sirona’s financials.

In 2017, Patterson ended its exclusive agreement, forcing Dentsply Sirona to acknowledge excess inventory and slowing sales. Over the next year, its financial misstatements unraveled, leading to a $1.2 billion goodwill impairment in August 2018, which caused $XRAY to drop 19%.

By December 2018, investors sued, alleging the company misled them about its financial health and engaged in anti-competitive practices to mask declining sales.

In December 2020, the SEC issued a cease-and-desist order, confirming that Dentsply Sirona failed to disclose key financial risks and that its revenue figures were artificially inflated.


What Can Investors Expect Now?


Dentsply Sirona ($XRAY) has agreed to an $84 million settlement with investors over claims that it misled them about financial reporting and anti-competitive practices.

If you were affected by this situation, you can file for a payout and receive your share of the settlement. You can check if you are eligible and find more details in the FAQ section below.
Case Type
US Securities Class Action
Case Status
Accepting Claims
Alleged Offence
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
0.4
Filing date
12/19/2018
Attorneys
Labaton Sucharow LLP; Robbins Geller Rudman & Dowd LLP
Defendants
Donald M. Casey Jr. ; Jorge M. Gomez; John Groetelaars
Administrator
A.B. Data Ltd
Settlement agreement date
2025-03-17
Court hearing date
09/10/2025
Exclusion deadline
08/20/2025
Objection deadline
08/20/2025
Attorney fee
$25,949,999
Trades matching type
FIFO

Frequently Asked Questions

Dentsply Sirona Inc

DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwi...

    Ticker
    XRAY.US
    ISIN
    US24906P1093
    CIK
    0000818479
    Sector
    Healthcare
    Industry
    Medical Instruments & Supplies
    Country
    USA
    Address
    13320 Ballantyne Corporate Place, Charlotte, NC, United States, 28277-3607